Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03285490 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
A Phase 3 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
NCT03285490 is a Phase 3 study that has completed, run by Almirall, S.A.. The registered enrollment target is 351 participants.
The verdict
NCT03285490, a Phase 3 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
Study Summary
This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the face or scalp.
Interventions
- DRUG Placebo
- DRUG KX2-391 Ointment 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2019-04-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03285490
The ClinicalTrials.gov registry entry for NCT03285490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03285490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03285490 about?
NCT03285490 is a clinical study titled "A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)". This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the face or scalp.
What is the current status of trial NCT03285490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2017-09-15. Estimated completion is 2019-04-24.
What interventions are being tested in trial NCT03285490?
The interventions under investigation include: Placebo (DRUG), KX2-391 Ointment 1% (DRUG).
Who is sponsoring clinical trial NCT03285490?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.